Visual Abstract of WCN 2025 presentation: Cumulative effects of the aldosterone synthase inhibitor vicadrostat combined with empagliflozin on albuminuria in people with CKD

Rossing, Peter; Hauske, Sibylle; Cronin, Lisa; Lambers Heerspink, Hiddo; Meyerhoff, Juliane; Shah, Shimoli; Sun, Zhichao; de Zeeuw, Dick; Tuttle, Katherine R

doi:10.60915/Boehringer-figshare.28417013.v1

Visual Abstract of WCN 2025 presentation: Cumulative effects of the aldosterone synthase inhibitor vicadrostat combined with empagliflozin on albuminuria in people with CKD

conference contribution

posted on 2025-02-14, 13:37 authored by Peter Rossing, Sibylle Hauske, Lisa Cronin, Hiddo Lambers Heerspink, Juliane Meyerhoff, Shimoli Shah, Zhichao Sun, Dick de Zeeuw, Katherine R Tuttle

The above is a visual abstract related to a poster presented at the World Congress of Nephrology (WCN), February 6–9, 2025.

Funding

This study was sponsored by Boehringer Ingelheim.

History

Disclaimer

The above is a visual abstract related to a poster presented at the World Congress of Nephrology (WCN), February 6–9, 2025. This visual abstract has been developed by the WCN Social Media Team and approved by the abstract’s authors. The content is not peer-reviewed. Unless otherwise specified, the content on this website has undergone a medical, legal, and regulatory (MLR) review and medical scientific accuracy review by Boehringer Ingelheim.

Usage metrics

Keywords

chronic kidney disease BI 690517 aldosterone synthase inhibitor empagliflozin World congress of Nephrology Vicadrostat

Licence

CC BY 4.0

Visual Abstract of WCN 2025 presentation: Cumulative effects of the aldosterone synthase inhibitor vicadrostat combined with empagliflozin on albuminuria in people with CKD

Funding

This study was sponsored by Boehringer Ingelheim.

History

Disclaimer

Usage metrics

Categories

Keywords

Licence

Exports